3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous-Cell Non-Small-Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
Paclitaxel
12
pembrolizumab
7
Carboplatin
7
Cisplatin
6
Docetaxel
5
sargramostim
4
Taxes
4
Cyclophosphamide
4
Amifostine
4
Trastuzumab
3
Polymerase Chain Reaction
3
Nivolumab
3
Irinotecan
3
Gemcitabine
3
Etoposide
3
talazoparib
2
aldesleukin
2
Vorinostat
2
Vinorelbine
2
SS1(dsFv)PE38
2
Pemetrexed
2
Interleukin-12 Subunit p35
2
Interleukin-12
2
Immunoenzyme Techniques
2
Gene Expression Profiling
2
Flow Cytometry
2
Filgrastim
2
Erlotinib Hydrochloride
2
tocilizumab
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Ovarian Epithelial
×
bemarituzumab
×
Thoracic
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled